EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cannabinoids and Genetic Epilepsy Models: A Review with Focus on CDKL5 Deficiency Disorder

Sean Massey, Anita Quigley, Simone Rochfort iD, John Christodoulou iD, Nicole J Van Bergen iD

International Journal of Molecular Sciences · 07.10.2024 · 25 (19) · 10768

DOI: 10.3390/ijms251910768 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 07.10.2024. Verfasst von Sean Massey und 4 weiteren Autor:innen. Beteiligte Einrichtung: Brain and Mitochondrial Research Group, Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, VIC 3052, Australia. Hauptthemen laut MEDLINE: Cannabinoids, Epileptic Syndromes, Spasms, Infantile. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: State Government of Victoria's Operational Infrastructure Support Program, Foundation for Children Project Grant, Murdoch Children's Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pediatric genetic epilepsies, such as CDKL5 Deficiency Disorder (CDD), are severely debilitating, with early-onset seizures occurring more than ten times daily in extreme cases. Existing antiseizure drugs frequently prove ineffective, which significantly impacts child development and diminishes the quality of life for patients and caregivers. The relaxation of cannabis legislation has increased research into potential therapeutic properties of phytocannabinoids such as cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC). CBD’s antiseizure properties have shown promise, particularly in treating drug-resistant genetic epilepsies associated with Lennox–Gastaut syndrome (LGS), Dravet syndrome (DS), and Tuberous Sclerosis Complex (TSC). However, specific research on CDD remains limited. Much of the current evidence relies on anecdotal reports of artisanal products lacking accurate data on cannabinoid composition. Utilizing model systems like patient-derived iPSC neurons and brain organoids allows precise dosing and comprehensive exploration of cannabinoids’ pharmacodynamics. This review explores the potential of CBD, THC, and other trace cannabinoids in treating CDD and focusing on clinical trials and preclinical models to elucidate the cannabinoid’s potential mechanisms of action in disrupted CDD pathways and strengthen the case for further research into their potential as anti-epileptic drugs for CDD. This review offers an updated perspective on cannabinoid’s therapeutic potential for CDD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabinoidsEpileptic SyndromesSpasms, InfantileHumansAnimalsAnticonvulsantsCannabidiolEpilepsyLennox Gastaut SyndromeProtein Serine-Threonine KinasesDisease Models, Animal

Stichwörter der Autor:innen

CBDCDDCDKL5cannabidiolcannabinoidsrefractory epilepsy

Substanzen

CannabinoidsAnticonvulsantsCannabidiolCDKL5 protein, humanProtein Serine-Threonine Kinases

Autor:innen und Institutionen

  • Brain and Mitochondrial Research Group, Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, VIC 3052, Australia.
  • Electrical and Biomedical Engineering, School of Engineering, RMIT University, Melbourne, VIC 3000, Australia.
  • Aikenhead Centre for Medical Discovery, St. Vincent's Hospital, Melbourne, VIC 3065, Australia.
  • Centre for Clinical Neuroscience and Neurological Research, St. Vincent's Hospital, Melbourne, VIC 3065, Australia.
  • Department of Medicine, University of Melbourne, Melbourne, VIC 3065, Australia.
  • School of Applied Systems Biology, La Trobe University, Bundoora, VIC 3083, Australia.

ORCID-Profile: Simone Rochfort, John Christodoulou, Nicole J Van Bergen

Förderung

  • State Government of Victoria's Operational Infrastructure Support Program
  • Foundation for Children Project Grant
  • Murdoch Children's Research Institute
  • Million Dollar Bike Ride pilot grant from the Orphan Disease Center of the University of Pennsylvania
  • CDKL5 Forum Junior Fellowship from the Loulou Foundation
  • Medical Research Future Funds (MRFF) Stem Cell Therapies Mission
  • VESKI
  • Royal Children's Hospital Foundation

Zitieren

APA

Massey, S., Quigley, A., Rochfort, S., Christodoulou, J., & Van Bergen, N. J. (2024). Cannabinoids and Genetic Epilepsy Models: A Review with Focus on CDKL5 Deficiency Disorder. International Journal of Molecular Sciences, 25(19), 10768. https://doi.org/10.3390/ijms251910768

Vancouver

Massey S, Quigley A, Rochfort S, Christodoulou J, Van Bergen NJ. Cannabinoids and Genetic Epilepsy Models: A Review with Focus on CDKL5 Deficiency Disorder. International Journal of Molecular Sciences. 2024;25(19):10768. doi:10.3390/ijms251910768

BibTeX
@article{Massey2024,
  author = {Massey, Sean and Quigley, Anita and Rochfort, Simone and Christodoulou, John and Van Bergen, Nicole J},
  title = {Cannabinoids and Genetic Epilepsy Models: A Review with Focus on CDKL5 Deficiency Disorder},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {19},
  pages = {10768},
  doi = {10.3390/ijms251910768}
}
Kostenlos starten →